Results 61 to 70 of about 45,099 (151)

Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer

Tumor Biology, 2016
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer-related deaths. The nucleoside analog gemcitabine has been the cornerstone of adjuvant chemotherapy in PDAC for decades. However, gemcitabine resistance develops within weeks of chemotherapy initiation, which might be intrinsic to cancer cells and influenced by tumor microenvironment ...
Yang, Liu, Fan, Li, Feng, Gao, Lingxi, Xing, Peng, Qin, Xingxin, Liang, Jiajie, Zhang, Xiaohui, Qiao, Lizhou, Lin, Qian, Zhao, Lianfang, Du   +10 more
openaire   +2 more sources

lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer

Molecular Therapy: Nucleic Acids, 2018
Dysregulated long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) mediating chemotherapeutic drug effects and metastasis in pancreatic cancer (PC) are key reasons for the poor prognosis of this disease.
Bingyan Liu, Shaoqiu Wu, Jun Ma, Shuo Yan, Zhengguang Xiao, Linhuang Wan, Feng Zhang, Mingyi Shang, Aiwu Mao   +8 more
doaj   +1 more source

Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer

International Journal of Oncology, 2015
Controversial effects of thalidomide for solid malignancies have been reported. In the present study, we evaluate the effects of thalidomide for transitional cell carcinoma (TCC), the most common type of bladder cancer. Thalidomide precipitates were observed when its DMSO solution was added to the culture medium.
Yen Ta, Huang, Chuan Chu, Cheng, Ted H, Chiu, Pei Chun, Lai   +3 more
openaire   +3 more sources

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

Journal of Translational Medicine
Background With poor prognosis and high mortality, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Standard of care therapies for PDAC have included gemcitabine for the past three decades, although resistance often ...
Mariam M. Konaté, Julia Krushkal, Ming-Chung Li, Li Chen, Yuri Kotliarov, Alida Palmisano, Rini Pauly, Qian Xie, P. Mickey Williams, Lisa M. McShane, Yingdong Zhao   +10 more
doaj   +1 more source

Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2010
Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer. Our previous experimental chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the ...
Wolfgang Hagmann, Ralf Jesnowski, Johannes Matthias Löhr   +2 more
doaj   +1 more source

Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids.

PLoS ONE
BackgroundPancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic advancements and rapid development of treatment resistance.
Jonathan Barajas, Zhi Yang, Edward Agyare, Xueyou Zhu, Saun-Joo Yoon, Bo Han   +5 more
doaj   +1 more source

Enhanced expression of ten‐eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P‐glycoprotein expression

Cancer Medicine, 2019
Increasing evidence revealed that ten‐eleven translocation 1 (TET1) plays an important role in tumorigenesis and chemoresistance, but its functions in gemcitabine resistance in cholangiocarcinoma (CCA) remain unknown.
Chuanxu Wang, Hua Ye, Lei Zhang, Yayu Cheng, Shifeng Xu, Ping Zhang, Zijie Zhang, Jimin Bai, Fangkang Meng, Lin Zhong, Guangjun Shi, Hao Li   +11 more
doaj   +1 more source

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Journal of Cancer, 2011
A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer.
Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
doaj  

EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer

BMC Cancer
Background Gemcitabine is a cornerstone drug for the treatment of all stages of pancreatic cancer and can prolong the survival of patients with pancreatic cancer, but resistance to gemcitabine in pancreatic cancer patients hinders its efficacy.
Zhe Yang, Feiran Chen, Dafu Wei, Fengping Chen, Haixing Jiang, Shanyu Qin   +5 more
doaj   +1 more source

The underlying mechanism of microRNA-21 in gemcitabine resistant breast cancer cells

Zhongguo aizheng zazhi, 2015
Background and purpose: Gemcitabine-based chemotherapy has been shown to have significant activity and favourable safety in metastatic breast cancer patients, but the effectiveness is limited due to drug resistance.
吴振华, 陶中华, 张剑
doaj